1. Introduction {#sec1}
===============

The extensive and intensive use of antibiotics has led to the emergence of resistant strains of bacteria. During the last few years, only three new types of antibiotics have been developed for clinical use \[[@B1]\]. Antimicrobial peptides have been identified from a wide variety of sources, including bacteria, insects, plants, and animals \[[@B2], [@B3]\]. Most native antimicrobial peptides are effective against a broad spectrum of pathogens but can also be toxic to normal cells \[[@B4]\].

The intensive study of the structure and function of antimicrobial peptides has led to the development and clinical application of many peptides with enhanced activity and low toxicity; these peptides have been developed through sequence splicing, amino acid substitution, and changing the ratio of hydrophobic amino acids \[[@B5]--[@B7]\]. Among them, *α*-helical antimicrobial peptides are one of the most studied types \[[@B8]\]. CP26, composed of the N-terminal 8 amino acid residues of cecropin A1 and the N-terminal 18 amino acid residues of melittin, has high antimicrobial activity and low toxicity \[[@B9]\]. P18, composed of 8 amino acid residues of the N-terminus of cecropin A1 and the N-terminal 12 amino acid residues of magainin 2, showed satisfactory antimicrobial activity and no toxicity \[[@B10]\].

In this study, CP26 and P18 were chosen as template peptides for the synthesis of CP-P, which is composed of amino acids 1 to 11 at the N-terminus (KWKSFIKKLTS) of CP26 and amino acids 10 to 18 at the C-terminus (KFLHLAKKF) of P18. CP-P was modified to yield a number of peptides with single amino acid substitutions at different sites on the polar or nonpolar faces, and their therapeutic indices (MIC/MHC) were evaluated against *Pseudomonas aeruginosa*. The in vitro activities of the selected peptides with high therapeutic indices were evaluated against a set of multiresistant clinical isolates of both Gram-positive and Gram-negative pathogens. The results indicate that the modifications changed the antimicrobial activities and hemolytic toxicities. Among the derivatives, K11 exhibited a high therapeutic index and may have potential for use in further studies.

2. Materials and Methods {#sec2}
========================

2.1. Bacterial Strains {#sec2.1}
----------------------

Twenty-two clinical isolates and night standard laboratory strains were used in this study: 4 *Acinetobacter baumannii*, 4 *Pseudomonas aeruginosa,*3 *Staphylococcus epidermidis*, and 6 *Klebsiella pneumonia* (Changhai Hospital, Shanghai, China); 5 methicillin-resistance*Staphylococcus aureus* (Ruijin Hospital, Shanghai, China); *Staphylococcus aureus*CMCC26003; *Bacillus subtilis* DB430;*Bacillus pumilus*CMCC63202; *Micrococcus luteus* CMCC28001; *E. coli*ATCC8099; *Klebsiella pneumoniae*CMCC46117;*Salmonella paratyphi*B CMCC50094; *Pseudomonas aeruginosa*CMCC10104; *Micrococcus*S1.634. In addition, *Pseudomonas aeruginosa*CMCC10104 was used during the design of the peptides for evaluating antimicrobial activities. All strains were cultured on Mueller-Hinton medium.

2.2. Design of Peptides {#sec2.2}
-----------------------

CP-P was designed by splicing the sequences of CP26 and P18. S16, which has a single amino acid change at the 16th site of CP-P, served as a template peptide from which several peptides were derived by single amino acid substitution at different sites. All of the peptide sequences are listed in [Table 1](#tab1){ref-type="table"}.

2.3. Synthesis and Purification of Peptides {#sec2.3}
-------------------------------------------

The syntheses of the peptides CP26, P18, CP-P, S16, and the S16 derivatives (a total of 23) were carried out by solid-phase peptide synthesis (SPPS) \[[@B11]\]. The crude peptides were purified by RP-HPLC using a Kromasil C18-5 column at a flow rate of 1 mL/min with a linear AB gradient (1% acetonitrile/min); mobile phase A was 0.1% trifluoroacetic in 100% water, and mobile phase B was 0.1% trifluoroacetic in 100% acetonitrile. The identities of the purified peptides were confirmed by mass spectrometry.

2.4. Circular Dichroism (CD) {#sec2.4}
----------------------------

CD spectra were obtained with a Jasco J-710 instrument (Jasco, Tokyo, Japan) utilizing quartz cells with a 2 mm path length and peptide concentrations of 100 *μ*M in a 10 mM sodium phosphate buffer with a pH of 7.5 containing 50% trifluoroethanol. Each spectrum was obtained from an average of 5 pairs of duplicates, and the percentage helicity of each peptide was determined \[[@B12]\].

2.5. Measurement of the Antibacterial Activity {#sec2.5}
----------------------------------------------

The antibacterial activities of the different peptides were evaluated using the minimum inhibitory concentration (MIC). The process followed the standard microtiter dilution method in LB medium without salt. Briefly, bacteria were grown overnight in LB at 37°C and diluted in the same medium. Then, 100 *μ*L of the medium was dispensed into each well of a 96-well plate. The number of bacteria was between 10^4^ and 10^5^ CFU/mL. Serial dilutions of peptides were performed consecutively in each well in 10 *μ*L. Plates were incubated at 37°C for 24 h; then, the OD~620~ was measured to determine the MIC of each peptide \[[@B13]\].

2.6. Measurement of Hemolytic Activity (MHC) {#sec2.6}
--------------------------------------------

The MHCs were measured by the method as described in Chen et al. \[[@B7]\]: peptides were added to 1% human erythrocytes in phosphate-buffered saline (0.08 mol/L NaCl, 0.043 mol/L Na~2~HPO~4~, 0.011 mol/L KH~2~PO~4~) and then kept at 37°C for 1 h in microtiter plates. The supernatants were collected by centrifugation (800 g), and the OD~562~ of each supernatant was determined. We chose a 0.1% Triton X-100 solution as the positive control because this solution causes the total release of hemoglobin. We defined the MHC as the highest peptide concentration that caused no detectable release of hemoglobin (the ratio of the OD~562~ for the peptide solution to the OD~562~ for the positive control should be less than 1%).

3. Results {#sec3}
==========

3.1. Design and Construction of Peptides {#sec3.1}
----------------------------------------

All of the peptides were designed based on a CP-P template, which had a higher therapeutic index than P18 and P26. S16, a derivative of CP-P with only one amino acid substitution at the 16th site, exhibited an 8-fold on the therapeutic index. This result indicates that a polar amino acid substitution on the nonpolar face could decrease the amphipathicity and influence the antimicrobial activity to some extent. [Figure 1](#fig1){ref-type="fig"} \[[@B14]\] shows the helical wheel structure of CP-P, which illustrates the polar and non-polar faces of CP-P clearly. We chose specific sites for single amino acid substitutions, constructed a series of peptides and then calculated the therapeutic index of all of the derivatives.

3.2. The Purification and Determination of the Molecular Confirmation of the Peptides {#sec3.2}
-------------------------------------------------------------------------------------

After purification, the designed peptides were analyzed by RP-HPLC, which showed that their purities were greater than 90%. [Figure 2](#fig2){ref-type="fig"} shows that peptide S16 reached a purity of 92.3% after purification. The S16 peak was collected and analyzed by mass spectrometry. [Table 1](#tab1){ref-type="table"} shows that the mass spectrometry results of the synthetic peptides matched well with those calculated by BioPerl \[[@B15]\].

3.3. Evaluation of the Designed Peptides {#sec3.3}
----------------------------------------

After the mutation of the 16th site to serine (S16), the MIC decreased to 1/4 of that of CP-P ([Table 2](#tab2){ref-type="table"}). [Table 2](#tab2){ref-type="table"} also provides information about other peptides that are based on modifications of S16 by amino acid substitutions. Among these 21 peptides, peptide K11 showed the highest efficacy, with an MIC of 1.6 *μ*g/mL, an MHC of more than 500 *μ*g/mL and a therapeutic index of 320.

The hydrophobic moments were determined with the HeliQuest web server \[[@B16]\], which can be used to evaluate amphipathicity. The percent helix values were determined based on CD spectra.

3.4. Antimicrobial Activity Against Clinical *Acinetobacter Baumannii* Isolates {#sec3.4}
-------------------------------------------------------------------------------

After comparison, three designed peptides, S16, K11, and P18, were chosen to use in MIC tests on four strains of clinically isolated *Acinetobacter baumannii*. [Table 3](#tab3){ref-type="table"} illustrates that peptide K11 had the lowest MICs for the four strains of *Acinetobacter baumannii*; these MICs were between 0.8 and 3.25 *μ*g/mL. Upon consideration of this result, we evaluated the antimicrobial activity of K11 against clinical isolates of both Gram-positive and Gram-negative pathogens.

3.5. Antimicrobial Activity of Peptide K11 Against Different Bacteria {#sec3.5}
---------------------------------------------------------------------

Similar to the results above, peptide K11 had a lower MIC than the other designed peptides. [Table 4](#tab4){ref-type="table"} shows the MICs of K11 against different bacteria, revealing that K11 exhibited broad-spectrum antimicrobial activity.

3.6. Antimicrobial Activities of Peptide K11 Against Clinical Isolates {#sec3.6}
----------------------------------------------------------------------

The results of MIC tests on different clinical bacterial isolates can be found in [Table 5](#tab5){ref-type="table"}. The clinically isolated bacteria included 5 strains of MRSA, 4 strains of *Pseudomonas aeruginosa*, 3 strains of *Staphylococcus epidermidis* and 6 strains of *Klebsiella pneumonia*. Peptide K11 exhibited a low MIC for almost all of the strains of bacteria, which indicated that this peptide has a high antimicrobial activity against several clinically isolated drug-resistant bacteria.

4. Discussion {#sec4}
=============

To design novel antimicrobial peptides with enhanced biological properties, we searched native antimicrobial peptides and selected CP26 and P18 as frameworks. CP26 and P18 have been reported to be two *α*-helical peptides with high antimicrobial activities. Starting with CP26 and P18, we designed and constructed a dozen novel peptides by sequence splicing and amino acid substitution. Several of these peptides had lower MICs and higher therapeutic indices than CP26 and P18. Among them, K11 showed the maximum antimicrobial activity and minimum eukaryotic cell toxicity, with an MIC 1/16 of that of P18 and a 32-fold higher therapeutic index than P18.

Recent studies on *α*-helical antimicrobial peptides have revealed that the amphipathic structure plays a primary role in the antimicrobial activity of these compounds. The reduction of antimicrobial activity resulting from the enhanced ability of self-aggregation caused by increasing amphipathicity has been reported \[[@B17]\]. The mechanism responsible for this effect may be the reduction of the effective molecular number after self-aggregation. In our study, we used HeliQuest to calculate the hydrophobic moment of peptides to evaluate the amphipathicity and came to the conclusion that high amphipathicity reduced the therapeutic index. S16 has a lower hydrophobic moment than CP-P (0.596 to 0.648) and was found to have a higher therapeutic index (160 to 20). Peptides L10 and D11 have high hydrophobic moments (0.632 and 0.631, resp.) and exhibited low therapeutic indices (\<20). The MICs increased from 3.125 *μ*g/mL for S16 to 12.5 *μ*g/mL and 25 *μ*g/mL, and the MHCs decreased from \>500 *μ*g/mL for S16 to \<125 *μ*g/mL. These results confirm the conclusion above, but high hydrophobic moments may also lead to increased antibacterial activities and decreased hemolytic activities. The results agree with the results of other studies that there is a threshold hydrophobicity at which optimal antimicrobial activity can be achieved \[[@B18]\]. In this study, K11 reached a therapeutic index of 320 and has a high hydrophobic moment (0.642).

We found that substitutions at certain specific sites (9, 11, and 13 from the N-terminus) can change the antimicrobial activity of S16 more effectively. The 9th residue of S16 is L, which is on the nonpolar face. If a polar amino acid were substituted at this site, there could be an increase in the MIC. R9, S9, and K9 are three derivatives that showed high MICs (\>50 *μ*g/mL) and decreased hydrophobic moments (0.494, 0.529, and 0.495, resp.). The substitutions at the 11th and 13th sites with opposite polar amino acids can also lead to significant increases in the MIC and decreases in the amphipathicity. We think that this structural implication should be investigated more closely in future studies.

The net positive charge on the polar face is important for the antimicrobial and hemolytic activities of antimicrobial peptides \[[@B19]\]. We constructed K11 by changing S to K at position 11 on the polar face of S16. This one addition to the net charge resulted in K11 showing the best biological properties among the tested peptides.

In conclusion, our results showed that the therapeutic index of a peptide depends on several factors. Modification of specific sites can change the amphipathicity to different extents, which can be used to predict the antimicrobial activity. In our study, we found a highly effective peptide, S16, and used it as template to establish a series of peptides with single amino acid substitutions. Among these peptides, K11 showed strong therapeutic action against antibiotic-resistant clinical isolates of both Gram-positive and Gram-negative bacteria, making it a promising antimicrobial peptide candidate for further study, especially in vivo studies and clinical tests.
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![Helical wheel structure and sequence of peptide CP-P.](IJMB2012-764834.001){#fig1}

![Analysis of the purity of peptide S16 by HPLC](IJMB2012-764834.002){#fig2}

###### 

Peptide sequences.

  Peptide   Sequence                           MW (Calc)^a^   MW (Deter)^b^
  --------- ---------------------------------- -------------- ---------------
  CP26      KWKSFIKKLTSAAKKVVTTAKPLISS-NH~2~   2859.7         2860.5
  P18       KWKLFKKIPKFLHLAKKF-NH~2~           2299.4         2300.5
  CP-P      KWKSFIKKLTSKFLHLAKKF-NH~2~         2480.1         2479.1
  S16       KWKSFIKKLTSKFLHSAKKF-NH~2~         2453           2452.1
  F2        KFKSFIKKLTSKFLHSAKKF-NH~2~         2415           2414.1
  N3        KWNSFIKKLTSKFLHSAKKF-NH~2~         2439.9         2439.1
  K6        KWKSFKKKLTSKFLHSAKKF-NH~2~         2469           2468.1
  N7        KWKSFINKLTSKFLHSAKKF-NH~2~         2439.9         2438.9
  A9        KWKSFIKKAKTSFLHSAKKF-NH~2~         2411.9         2410.7
  K9        KWKSFIKKKTSKFLHSAKKF-NH~2~         2469           2468.1
  S9        KWKSFIKKSTSKFLHSAKKF-NH~2~         2427.9         2426.7
  R9        KWKSFIKKRTSKFLHSAKKF-NH~2~         2497           2496.1
  A10       KWKSFIKKLASKFLHSAKKF-NH~2~         2424           2424.1
  L10       KWKSFIKKLLSKFLHSAKKF-NH~2~         2466           2465.1
  D11       KWKSFIKKLTDKFLHSAKKF-NH~2~         2482           2481.7
  K11       KWKSFIKKLTKKFLHSAKKF-NH~2~         2495.1         2494.4
  L11       KWKSFIKKLTLKFLHSKKKF-NH~2~         2480.1         2479.2
  A13       KWKSFIKKLTSKALHSAKKF-NH~2~         2377.9         2378.1
  K13       KWKSFIKKLTSKKLHSAKKF-NH~2~         2435           2434.3
  K17       KWKSFIKKLTSKFLHSKKKF-NH~2~         2511.1         2510.2
  D18       KWKSFIKKLTSKFLHSADKF-NH~2~         2440.9         2440.2
  N18       KWKSFIKKLTSKFLHSANKF-NH~2~         2439.9         2440
  N20       KWKSFIKKLTSKFLHSAKKN-NH~2~         2420.9         2419.6

^a^Calculated using BioPerl.

^b^Determined using mass spectrometry.

###### 

The MICs, MHCs, and therapeutic indices of the designed peptides.

  Peptide   MIC (*μ*g/mL)   MHC (*μ*g/mL)   Therapeutic index   Hydrophobicity   Hydrophobic moment   %Helix   Net charge
  --------- --------------- --------------- ------------------- ---------------- -------------------- -------- ------------
  P18       25              250             10                  0.486            0.405                N        7
  CP-P      12.5            250             20                  0.411            0.648                63.2     7
  S16       3.125           \>500           160                 0.323            0.596                71.8     7
  F2        12.5            250             20                  0.3              0.574                N        7
  N3        12.5            N               N                   0.343            0.599                72.5     6
  K6        12.5            N               N                   0.184            0.471                N        8
  N7        12.5            \>500           40                  0.343            0.586                72.1     6
  K9        \>50            N               N                   0.189            0.495                51.5     8
  S9        50              \>500           10                  0.236            0.529                68.2     7
  R9        \>50            N               N                   0.188            0.494                N        8
  A9        25              \>500           20                  0.254            0.496                64.6     7
  L10       12.5            \<125           10                  0.395            0.632                72.1     7
  A10       12.5            250             20                  0.326            0.597                72.5     7
  D11       25              \>500           20                  0.287            0.631                71.6     6
  K11       1.6             \>500           320                 0.276            0.642                67.4     8
  L11       \>50            N               N                   0.411            0.513                N        7
  A13       6.25            \>500           80                  0.249            0.522                45.9     7
  K13       \>50            N               N                   0.184            0.457                62.6     8
  K17       12.5            \>500           40                  0.258            0.551                58.7     8
  D18       25              \>500           20                  0.343            0.587                51.4     5
  N18       6.25            \>500           80                  0.343            0.58                 37.2     6
  N20       6.25            \>500           80                  0.204            0.483                N        7

Note: "N" signifies that the data were not determined.

###### 

MIC tests on four strains of clinical *Acinetobacter baumannii*isolates.

  Peptide   MIC (*μ*g /mL)                  
  --------- ---------------- ------- ------ -------
  P18       6.25             25      12.5   12.5
  S16       3.125            6.25    6.25   3.125
  K11       0.8              3.125   3.25   1.6

###### 

MICs of peptide K11 for different bacteria.

  ------------------------------------------------------------------------
                                Bacteria                   MIC (*μ*g/mL)
  ----------------------------- -------------------------- ---------------
  Gram-positive bacteria        *Staphylococcus aureus*\   0.5
                                CMCC26003                  

  *Bacillus subtilis*\          2                          
  DB430                                                    

  *Bacillus pumilus*\           0.5                        
  CMCC63202                                                

  *Soluble wall Micrococcus*\   1                          
  S1.634                                                   

  *Micrococcus luteus*\         2                          
  CMCC28001                                                

                                                           

  Gram-negative bacteria        *E. coli*\                 0.5
                                ATCC8099                   

  *Klebsiella pneumoniae*\      2                          
  CMCC46117                                                

  *Salmonella paratyphi* B\     2                          
  CMCC50094                                                

  *Pseudomonas aeruginosa*\     4                          
  CMCC10104                                                
  ------------------------------------------------------------------------

###### 

MICs of K11 for clinically isolated bacteria.

  Bacteria                           MIC (*μ*g/mL)
  ---------------------------------- ---------------
  MRSA (5)                           0.25−4
  *Pseudomonas aeruginosa* (4)       1.0−8.0
  *Staphylococcus epidermidis* (3)   0.5−8
  *Klebsiella pneumonia* (6)         0.5−4.0
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